[go: up one dir, main page]

WO2008152822A1 - 医薬 - Google Patents

医薬 Download PDF

Info

Publication number
WO2008152822A1
WO2008152822A1 PCT/JP2008/001535 JP2008001535W WO2008152822A1 WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1 JP 2008001535 W JP2008001535 W JP 2008001535W WO 2008152822 A1 WO2008152822 A1 WO 2008152822A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
agent
medicinal
therapeutic agent
antibody therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/001535
Other languages
English (en)
French (fr)
Inventor
Andrew Nicol
Hirotake Tokuyama
Tomomi Hagi
Mie Nieda
Masato Muto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinet Co Ltd
Original Assignee
Medinet Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinet Co Ltd filed Critical Medinet Co Ltd
Priority to JP2009519171A priority Critical patent/JPWO2008152822A1/ja
Publication of WO2008152822A1 publication Critical patent/WO2008152822A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　モノクローナル抗体治療薬を投与した際に起こる体内でのＡＤＣＣをより向上させた医薬、治療・予防方法を提供することを課題とする。また、モノクローナル抗体治療薬の効果を向上させるためのアジュバントを提供する。 　ビスホスホネートとＩＬ－２とで活性化及び／又は増殖させたγδＴ細胞とモノクローナル抗体治療薬を組み合わせて医薬とすることにより、γδＴ細胞、モノクローナル抗体治療薬を、それぞれ単独で用いるよりも高い相乗的効果を有する医薬を提供することが可能となる。
PCT/JP2008/001535 2007-06-15 2008-06-13 医薬 Ceased WO2008152822A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009519171A JPWO2008152822A1 (ja) 2007-06-15 2008-06-13 医薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-159398 2007-06-15
JP2007159398 2007-06-15

Publications (1)

Publication Number Publication Date
WO2008152822A1 true WO2008152822A1 (ja) 2008-12-18

Family

ID=40129436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001535 Ceased WO2008152822A1 (ja) 2007-06-15 2008-06-13 医薬

Country Status (2)

Country Link
JP (1) JPWO2008152822A1 (ja)
WO (1) WO2008152822A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010063847A1 (en) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions for potentiating apoposis signals in tumour cells
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2015522543A (ja) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
WO2016005752A1 (en) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof
EP4119582A1 (en) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US12331316B2 (en) 2015-04-30 2025-06-17 Ucl Business Ltd T cell which expresses a gamma-delta t cell receptor (TCR) and a chimeric antigen receptor (CAR)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRINI S. ET AL.: "Retargeting of T-cell-receptor gamma/delta-pos. lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production", INTERNATIONAL JOURNAL OF CANCER, no. SUPPL. 4, 1989, pages 53 - 55 *
ROSSI J.-F. ET AL.: "Enhancing lysis of B cell lymphoma by innovative gamma delta T cell immunotherapies using agonist IPH1101 (phosphotim, BrHPP)", BLOOD, vol. 108, no. 11, 2006, pages 391B, XP008083238 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
WO2010063847A1 (en) * 2008-12-04 2010-06-10 Universite Victor Segalen Bordeaux 2 Compositions for potentiating apoposis signals in tumour cells
US12059464B2 (en) 2012-05-23 2024-08-13 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
KR20200140387A (ko) * 2012-05-23 2020-12-15 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
KR102514338B1 (ko) 2012-05-23 2023-03-28 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
JP2015522543A (ja) * 2012-05-23 2015-08-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
CN107412773A (zh) * 2012-05-23 2017-12-01 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
AU2013265637B2 (en) * 2012-05-23 2017-12-21 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2018002724A (ja) * 2012-05-23 2018-01-11 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
JP2018035155A (ja) * 2012-05-23 2018-03-08 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
AU2013265637B8 (en) * 2012-05-23 2018-04-26 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
JP2015518838A (ja) * 2012-05-23 2015-07-06 ガニメド ファーマシューティカルズ アーゲー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102188001B1 (ko) 2012-05-23 2020-12-07 가니메드 파마슈티칼스 게엠베하 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
JP2023038230A (ja) * 2012-05-23 2023-03-16 アステラス製薬株式会社 がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
CN104427999A (zh) * 2012-05-23 2015-03-18 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
KR20150027112A (ko) * 2012-05-23 2015-03-11 가니메드 파마슈티칼스 아게 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 조합 요법
EP4119582A1 (en) * 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2019104747A (ja) * 2012-05-23 2019-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法
WO2013174509A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2018201856B2 (en) * 2012-05-23 2020-06-18 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN107412773B (zh) * 2012-05-23 2021-04-06 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
JP2018197260A (ja) * 2013-02-20 2018-12-13 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
JP2020125329A (ja) * 2013-02-20 2020-08-20 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP7051931B2 (ja) 2013-02-20 2022-04-11 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2022088550A (ja) * 2013-02-20 2022-06-14 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP7681061B2 (ja) 2013-02-20 2025-05-21 アステラス製薬株式会社 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
JP2023123596A (ja) * 2013-02-20 2023-09-05 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP7299369B2 (ja) 2013-02-20 2023-06-27 ガニメド ファーマシューティカルズ ゲーエムベーハー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
JP2016510721A (ja) * 2013-02-20 2016-04-11 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
WO2016005752A1 (en) * 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
US10881688B2 (en) 2015-04-15 2021-01-05 Tc Biopharm Ltd Modified gamma delta T cells and uses thereof
US12331316B2 (en) 2015-04-30 2025-06-17 Ucl Business Ltd T cell which expresses a gamma-delta t cell receptor (TCR) and a chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
JPWO2008152822A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2008152822A1 (ja) 医薬
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
MX2022003132A (es) Composiciones de corticoesteroides administradas oralmente.
WO2008113834A3 (en) C5 antigens and uses thereof
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2009089494A3 (en) Pharmaceutical compositions
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
WO2012015741A3 (en) Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2007127273A3 (en) Methods and compositions for altering cell function
UA96076C2 (en) Use of trans-clomiphene
MX339116B (es) Tratamiento de esclerosis tuberosa.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2009012920A (es) Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
WO2011075822A8 (en) Immunogenic compositions and related methods
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
AU2013257482A1 (en) Methods and compositions for administration of oxybutynin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009519171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08764130

Country of ref document: EP

Kind code of ref document: A1